Wexford Capital’s BridgeBio Pharma BBIO Stock Holding History

Wexford Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$3.05M	Buy	50,000 +20,000	+67%	+$1.14M	0.46%	50
2021 Q1	$1.85M	Hold	30,000	–	–	0.28%	87
2020 Q4	$2.13M	Buy	+30,000	New	+$1.45M	0.33%	78
2020 Q1	–	Sell	-15,000	Closed	-$526K	–	104
2019 Q4	$526K	Buy	+15,000	New	+$416K	0.08%	104

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wexford Capital's BBIO Position: Q2 2021 in Review

Wexford Capital increased its BridgeBio Pharma (BBIO) stake by 67% in Q2 2021, buying an estimated $1.14M and bringing the position to 50,000 shares worth $3.05M. The position accounts for 0.46% of the portfolio, ranked #50.

Wexford Capital first reported a position in BBIO in Q4 2019 and has held it in 4 quarters since. 200 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

Wexford Capital held 50,000 shares of BridgeBio Pharma worth $3.05M as of Q2 2021.
Wexford Capital bought 20,000 BridgeBio Pharma shares in Q2 2021, an estimated $1.14M.
BridgeBio Pharma made up 0.46% of Wexford Capital's portfolio in Q2 2021, its #50 holding.
Wexford Capital first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 4 quarters since.
200 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Wexford Capital's 13F filing for Q2 2021, filed 16 Aug 2021.